MALVERN, Pa., July 15, 2024 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) announced today the launch of tiopronin delayed-release tablets, a generic version of Travere Therapeutics' THIOLA EC®.
"We're proud to provide high-quality, affordable choices to healthcare providers and their appropriate patients," said Scott Sims, Senior Vice President and General Manager, Endo Injectable Solutions & Generics. "The launch of tiopronin delayed-release tablets strengthens our generic product portfolio and underscores our reputation as a reliable supplier."
The medication is used in combination with high fluid intake, alkali (low acid), and dietary changes to help prevent the formation of one type (cystine) of kidney stones in certain adult and pediatric patients.
As a demonstration of its commitment to patients, Endo is offering copay assistance for those who meet eligibility requirements. To learn more about Endo's Patient Assistance Program, patients can call (833) 727-4357.
THIOLA EC® is a registered trademark of Mission Pharmacal Company. Read More >
Through our long-standing work in endocrinology, orthopedics, and urology, as well as in hospital systems and with retail generic medications, we have developed an unmatched understanding of those we serve. We will never stop learning how to make a real difference in people's lives. We partner with hospitals and healthcare systems to reduce complexity through life-enhancing solutions, innovating together to add value where it matters—from manufacturing to treatment—so that healthcare providers can focus on patient care. We deliver high-quality, affordable generic medicines to patients in need through excellence in development, manufacturing, and commercialization. Drawing from over four decades of experience in the U.S. generic pharmaceutical market, we have built a well-established reputation for compliance and exceptional customer service.
This post is related to:
Community / Retail Pharmacy Resources Generics, Brand Name, Biotech Health System Pharmacy Resources
